Nu-Med Plus Narrows Q1 Loss by 90% Amidst Zero Revenue
Ticker: NUMD · Form: 10-Q · Filed: May 22, 2025 · CIK: 1543637
| Field | Detail |
|---|---|
| Company | Nu-Med Plus, Inc. (NUMD) |
| Form Type | 10-Q |
| Filed Date | May 22, 2025 |
| Risk Level | high |
| Sentiment | bearish |
Sentiment: bearish
Topics: Medical Devices, Pre-Revenue, Small Cap, SEC Filing, Quarterly Report, High Risk, Loss Reduction
TL;DR
**NUMD's 90% loss reduction is a mirage; zero revenue means it's still a speculative bet.**
AI Summary
Nu-Med Plus, Inc. (NUMD) reported no revenue for the quarter ended March 31, 2025, consistent with its prior period. The company incurred a net loss of $1,000 for the three months ended March 31, 2025, a significant improvement from the net loss of $10,000 reported for the same period in 2024, representing a 90% reduction in net loss. This reduction was primarily due to decreased operating expenses. Nu-Med Plus, Inc. continues to operate as a smaller reporting company and is not an emerging growth company. The company confirmed it has filed all required reports under Section 13 or 15(d) of the Securities Exchange Act of 1934 during the past 12 months and is not a shell company. Its strategic outlook remains focused on its core business as a surgical and medical instruments and apparatus company, though specific operational changes or new product developments were not detailed in this filing.
Why It Matters
For investors, Nu-Med Plus's continued lack of revenue, despite a reduced net loss, signals a company still in a pre-commercial or early-stage phase, making it a high-risk investment. Employees might face uncertainty given the absence of sales, which could impact future growth and job security. Customers are not directly impacted by this financial report as there's no revenue generation to indicate product availability or market presence. The broader medical instruments market sees little competitive threat from NUMD at this stage, as it has yet to establish a revenue stream.
Risk Assessment
Risk Level: high — The risk level is high because Nu-Med Plus, Inc. reported no revenue for the quarter ended March 31, 2025, and the prior period, indicating a lack of commercial operations or product sales. While the net loss decreased by 90% from $10,000 to $1,000, this improvement is from a very low base and does not offset the fundamental risk of zero revenue generation.
Analyst Insight
Investors should approach Nu-Med Plus, Inc. with extreme caution, recognizing its pre-revenue status and high speculative nature. This filing suggests holding off on investment until concrete revenue generation and a clear path to profitability are demonstrated.
Financial Highlights
- debt To Equity
- N/A
- revenue
- $0
- operating Margin
- N/A
- total Assets
- N/A
- total Debt
- N/A
- net Income
- -$1,000
- eps
- N/A
- gross Margin
- N/A
- cash Position
- N/A
- revenue Growth
- 0.0%
Revenue Breakdown
| Segment | Revenue | Growth |
|---|---|---|
| Surgical and medical instruments and apparatus | $0 | 0.0% |
Key Numbers
- $0 — Revenue (No revenue generated for Q1 2025 or Q1 2024, indicating pre-commercial stage.)
- $1,000 — Net Loss (Net loss for Q1 2025, a 90% reduction from Q1 2024.)
- $10,000 — Prior Net Loss (Net loss for Q1 2024, showing significant improvement in expense management.)
- 90% — Loss Reduction (Percentage decrease in net loss from Q1 2024 to Q1 2025.)
Key Players & Entities
- Nu-Med Plus, Inc. (company) — registrant in 10-Q filing
- SEC (regulator) — recipient of 10-Q filing
- $1,000 (dollar_amount) — net loss for Q1 2025
- $10,000 (dollar_amount) — net loss for Q1 2024
- Utah (company) — state of incorporation for Nu-Med Plus, Inc.
- Port Jefferson, NY (company) — business address for Nu-Med Plus, Inc.
- 000-54808 (regulator) — Commission File Number for Nu-Med Plus, Inc.
- March 31, 2025 (company) — end of the reporting period for the 10-Q
- 90% (dollar_amount) — reduction in net loss from Q1 2024 to Q1 2025
FAQ
What was Nu-Med Plus, Inc.'s revenue for the quarter ended March 31, 2025?
Nu-Med Plus, Inc. reported no revenue for the quarter ended March 31, 2025, consistent with the prior period, indicating a lack of commercial sales.
How much was Nu-Med Plus, Inc.'s net loss in Q1 2025?
Nu-Med Plus, Inc. incurred a net loss of $1,000 for the three months ended March 31, 2025, a significant improvement from the $10,000 net loss in Q1 2024.
Did Nu-Med Plus, Inc. reduce its net loss in Q1 2025 compared to Q1 2024?
Yes, Nu-Med Plus, Inc. reduced its net loss by 90%, from $10,000 in Q1 2024 to $1,000 in Q1 2025, primarily due to decreased operating expenses.
Is Nu-Med Plus, Inc. considered a shell company?
No, Nu-Med Plus, Inc. indicated by check mark that it is not a shell company as defined in Rule 12b-2 of the Exchange Act.
Has Nu-Med Plus, Inc. filed all required SEC reports?
Yes, Nu-Med Plus, Inc. confirmed it has filed all reports required by Section 13 or 15(d) of the Securities Exchange Act of 1934 during the past 12 months.
What is Nu-Med Plus, Inc.'s business address?
Nu-Med Plus, Inc.'s business address is 640 Belle Terre Rd. 2 E, Port Jefferson, NY 11777.
What is the primary industry classification for Nu-Med Plus, Inc.?
Nu-Med Plus, Inc. is classified under Surgical & Medical Instruments & Apparatus [3841] according to its Standard Industrial Classification.
What does Nu-Med Plus, Inc.'s lack of revenue mean for investors?
The lack of revenue for Nu-Med Plus, Inc. means it is still in a pre-commercial stage, posing a high investment risk as there are no sales to support its operations or future growth.
What is the significance of Nu-Med Plus, Inc. being a 'smaller reporting company'?
Being a 'smaller reporting company' means Nu-Med Plus, Inc. qualifies for certain scaled disclosure requirements, which can reduce compliance costs but also means less detailed information is publicly available compared to larger filers.
What was the filing date for Nu-Med Plus, Inc.'s 10-Q report?
The 10-Q report for Nu-Med Plus, Inc. was filed on May 22, 2025, for the quarterly period ended March 31, 2025.
Risk Factors
- Lack of Revenue Generation [high — financial]: The company reported $0 revenue for the quarter ended March 31, 2025, and the prior year period. This indicates a pre-commercial stage and a significant risk related to the ability to generate future sales and achieve profitability.
- Dependence on Future Product Development [medium — operational]: Nu-Med Plus, Inc. operates in the surgical and medical instruments sector but has not detailed specific operational changes or new product developments in this filing. Future success is contingent on the development and market acceptance of its products.
- Sustained Net Losses [medium — financial]: While the net loss for Q1 2025 was $1,000, a significant improvement from $10,000 in Q1 2024, the company continues to incur losses. This necessitates ongoing funding and poses a risk if capital cannot be secured or if operational efficiencies do not continue.
Industry Context
Nu-Med Plus, Inc. operates within the surgical and medical instruments and apparatus industry. This sector is characterized by innovation, stringent regulatory oversight (e.g., FDA approval), and competition from established players and emerging technologies. Companies in this space often require significant R&D investment and face long product development cycles.
Regulatory Implications
As a medical device company, Nu-Med Plus, Inc. is subject to regulatory scrutiny, primarily from the FDA in the United States. Compliance with manufacturing standards (e.g., Quality System Regulation) and product approval processes are critical. Failure to comply can lead to significant delays, fines, or product recalls.
What Investors Should Do
- Monitor revenue generation progress.
- Evaluate expense management strategies.
- Seek clarity on product development pipeline.
Glossary
- Smaller Reporting Company
- A company that meets certain criteria related to public float and annual revenues, allowing for scaled disclosure requirements. (Nu-Med Plus, Inc. qualifies as a smaller reporting company, which impacts the level of detail and complexity required in its SEC filings.)
- Emerging Growth Company
- A company that has not yet reached a certain size and revenue threshold, allowing for extended transition periods for adopting new accounting standards. (Nu-Med Plus, Inc. is not an emerging growth company, meaning it must comply with all new and revised financial accounting standards without extended transition periods.)
- Shell Company
- A company with no or nominal operations, and with little or no assets, often used for the purpose of 'inverting' a company or facilitating a merger. (Nu-Med Plus, Inc. explicitly states it is not a shell company, indicating it has ongoing operations and assets.)
Year-Over-Year Comparison
Nu-Med Plus, Inc. reported $0 revenue for the quarter ended March 31, 2025, consistent with the prior year's $0 revenue. The company significantly improved its financial performance by reducing its net loss by 90%, from $10,000 in Q1 2024 to $1,000 in Q1 2025, primarily due to decreased operating expenses. No new significant risks were detailed in this filing, and the company continues to operate as a smaller reporting company without emerging growth company status.
Filing Details
This Form 10-Q (Form 10-Q) was filed with the SEC on May 22, 2025 regarding Nu-Med Plus, Inc. (NUMD).